These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 17411025)

  • 1. Synthesis, biological testing, and binding mode prediction of 6,9-diarylpurin-8-ones as p38 MAP kinase inhibitors.
    Hauser DR; Scior T; Domeyer DM; Kammerer B; Laufer SA
    J Med Chem; 2007 May; 50(9):2060-6. PubMed ID: 17411025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors.
    Laufer SA; Domeyer DM; Scior TR; Albrecht W; Hauser DR
    J Med Chem; 2005 Feb; 48(3):710-22. PubMed ID: 15689155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissection of the recognition properties of p38 MAP kinase. Determination of the binding mode of a new pyridinyl-heterocycle inhibitor family.
    Soliva R; Gelpí JL; Almansa C; Virgili M; Orozco M
    J Med Chem; 2007 Jan; 50(2):283-93. PubMed ID: 17228870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.
    Goldstein DM; Alfredson T; Bertrand J; Browner MF; Clifford K; Dalrymple SA; Dunn J; Freire-Moar J; Harris S; Labadie SS; La Fargue J; Lapierre JM; Larrabee S; Li F; Papp E; McWeeney D; Ramesha C; Roberts R; Rotstein D; San Pablo B; Sjogren EB; So OY; Talamas FX; Tao W; Trejo A; Villasenor A; Welch M; Welch T; Weller P; Whiteley PE; Young K; Zipfel S
    J Med Chem; 2006 Mar; 49(5):1562-75. PubMed ID: 16509574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase.
    Frembgen-Kesner T; Elcock AH
    J Mol Biol; 2006 May; 359(1):202-14. PubMed ID: 16616932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase.
    Cogan DA; Aungst R; Breinlinger EC; Fadra T; Goldberg DR; Hao MH; Kroe R; Moss N; Pargellis C; Qian KC; Swinamer AD
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3251-5. PubMed ID: 18462940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tagged fragment method for evolutionary structure-based de novo lead generation and optimization.
    Liu Q; Masek B; Smith K; Smith J
    J Med Chem; 2007 Nov; 50(22):5392-402. PubMed ID: 17918924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theoretical and experimental design of atypical kinase inhibitors: application to p38 MAP kinase.
    McClure KF; Abramov YA; Laird ER; Barberia JT; Cai W; Carty TJ; Cortina SR; Danley DE; Dipesa AJ; Donahue KM; Dombroski MA; Elliott NC; Gabel CA; Han S; Hynes TR; Lemotte PK; Mansour MN; Marr ES; Letavic MA; Pandit J; Ripin DB; Sweeney FJ; Tan D; Tao Y
    J Med Chem; 2005 Sep; 48(18):5728-37. PubMed ID: 16134941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The three-dimensional structure of MAP kinase p38beta: different features of the ATP-binding site in p38beta compared with p38alpha.
    Patel SB; Cameron PM; O'Keefe SJ; Frantz-Wattley B; Thompson J; O'Neill EA; Tennis T; Liu L; Becker JW; Scapin G
    Acta Crystallogr D Biol Crystallogr; 2009 Aug; 65(Pt 8):777-85. PubMed ID: 19622861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p38 MAP kinase inhibitors. Part 6: 2-arylpyridazin-3-ones as templates for inhibitor design.
    Natarajan SR; Heller ST; Nam K; Singh SB; Scapin G; Patel S; Thompson JE; Fitzgerald CE; O'Keefe SJ
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5809-13. PubMed ID: 16945533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.
    Tamayo N; Liao L; Goldberg M; Powers D; Tudor YY; Yu V; Wong LM; Henkle B; Middleton S; Syed R; Harvey T; Jang G; Hungate R; Dominguez C
    Bioorg Med Chem Lett; 2005 May; 15(9):2409-13. PubMed ID: 15837335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3,5-Disubstituted quinolines as novel c-Jun N-terminal kinase inhibitors.
    Jiang R; Duckett D; Chen W; Habel J; Ling YY; LoGrasso P; Kamenecka TM
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6378-82. PubMed ID: 17911023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking.
    Ravindra GK; Achaiah G; Sastry GN
    Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.
    Laufer SA; Hauser DR; Domeyer DM; Kinkel K; Liedtke AJ
    J Med Chem; 2008 Jul; 51(14):4122-49. PubMed ID: 18578517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low ATP competitiveness and outstanding whole blood activity.
    Fischer S; Wentsch HK; Mayer-Wrangowski SC; Zimmermann M; Bauer SM; Storch K; Niess R; Koeberle SC; Grütter C; Boeckler FM; Rauh D; Laufer SA
    J Med Chem; 2013 Jan; 56(1):241-53. PubMed ID: 23270382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
    Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
    J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and design of benzimidazolone based inhibitors of p38 MAP kinase.
    Hammach A; Barbosa A; Gaenzler FC; Fadra T; Goldberg D; Hao MH; Kroe RR; Liu P; Qian KC; Ralph M; Sarko C; Soleymanzadeh F; Moss N
    Bioorg Med Chem Lett; 2006 Dec; 16(24):6316-20. PubMed ID: 17010605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New modifications to the area of pyrazole-naphthyl urea based p38 MAP kinase inhibitors that bind to the adenine/ATP site.
    Moss N; Breitfelder S; Betageri R; Cirillo PF; Fadra T; Hickey ER; Kirrane T; Kroe RR; Madwed J; Nelson RM; Pargellis CA; Qian KC; Regan J; Swinamer A; Torcellini C
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4242-7. PubMed ID: 17560108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and optimization of p38 inhibitors via computer-assisted drug design.
    Goldberg DR; Hao MH; Qian KC; Swinamer AD; Gao DA; Xiong Z; Sarko C; Berry A; Lord J; Magolda RL; Fadra T; Kroe RR; Kukulka A; Madwed JB; Martin L; Pargellis C; Skow D; Song JJ; Tan Z; Torcellini CA; Zimmitti CS; Yee NK; Moss N
    J Med Chem; 2007 Aug; 50(17):4016-26. PubMed ID: 17658737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.